1174335-83-1 Usage
General Description
Nintedanib is a small molecule tyrosine kinase inhibitor that primarily targets receptors for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (FGF). It is approved for the treatment of idiopathic pulmonary fibrosis and advanced non-small cell lung cancer, where it has been shown to inhibit multiple pathways involved in angiogenesis and fibroblast proliferation, leading to reduced fibrosis and tumor growth. Nintedanib has also been investigated for its potential in treating other fibrotic diseases, such as systemic sclerosis and liver fibrosis, as well as various types of cancer. Despite its efficacy, it can cause adverse effects such as diarrhea, nausea, vomiting, and liver enzyme elevations, and requires careful monitoring and management.
Check Digit Verification of cas no
The CAS Registry Mumber 1174335-83-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,4,3,3 and 5 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1174335-83:
(9*1)+(8*1)+(7*7)+(6*4)+(5*3)+(4*3)+(3*5)+(2*8)+(1*3)=151
151 % 10 = 1
So 1174335-83-1 is a valid CAS Registry Number.
1174335-83-1Relevant articles and documents
Indolone derivative and pharmaceutical application thereof
-
, (2021/03/31)
The invention provides an indolone derivative and pharmaceutical application thereof. The structure of the indolone derivative is shown as a formula (A). Experimental results show that the compound provided by the invention has obviously improved pharmacokinetic properties than BIBF1120, has excellent inhibition effects on VEGFR, FGFR and PDGFR, can be used as a VEGFR, FGFR and/or PDGFR inhibitor,an angiogenesis inhibitor and a drug for preventing and/or treating various tumors including pharyngeal squamous cell carcinoma, and has a wide application prospect.
INTEDANIB SALTS AND SOLID STATE FORMS THEREOF
-
Page/Page column 12, (2012/06/01)
The present invention provides salts of Intedanib, crystalline forms of the salts of Intedanib, processes for their manufacture and their use in pharmaceutical compositions.
